Table 2.
IFNL3 and TLR2 genotypes among 688 HCV-positive cases and 94 HCV-negative BD.
| IFNL3 C > T (rs12979860) |
TLR-2 ins/del rs111200466) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | C/C (%) | C/T (%) | T/T (%) | MAF∗ | OR (95%CI) | Ins/Ins (%) | Ins/Del (%) | Del/Del (%) | MAF∗ | OR (95%CI)† | |
| Control subjects | |||||||||||
| BD | 94 | 42 (44.7) | 47 (50.0) | 5 (5.3) | 0.30 | Reference | 72 (76.4) | 21 (22.3) | 1 (1.4) | 0.12 | Reference |
| HCV infected patients with liver diseases | |||||||||||
| CHC | 148 | 44 (29.7) | 88 (59.4) | 16 (10.8) | 0.41 | 1.57 (1.1–2.3) p = 0.02 | 101 (68.2) | 41 (27.0) | 6 (4.7) | 0.16 | |
| Cirrhosis | 113 | 26 (23.0) | 66 (58.4) | 21 (18.6) | 0.48 | 2.10 (1.4–3.2) p < 0.001 | 82 (72.6) | 26 (23.0) | 5 (4.4) | 0.16 | |
| HCC | 144 | 42 (29.2) | 78 (54.2) | 24 (16.7) | 0.43 | 1.79 (1.2–2.6) p = 0.003 | 97 (67.4) | 32 (22.2) | 15 (10.4) | 0.21 | 1.97 (1.2–3.3) p = 0.011 |
| HCV infected patients with lymphoproliferative diseases | |||||||||||
| MC | 130 | 55 (42.3) | 59 (45.4) | 16 (12.3) | 0.35 | 86 (66.2) | 38 (29.2) | 6 (4.6) | 0.19 | 1.71 (1.0–2.9) p = 0.050 | |
| NHL | 108 | 41 (38.0) | 54 (50.0) | 13 (12.0) | 0.37 | 83 (76.9) | 24 (22.2) | 1 (0.9) | 0.12 | ||
| Total | 737 | 250 (33.9) | 392 (53.2) | 95 (12.9) | 0.40 | 521 (70.7) | 182 (24.7) | 34 (4.6) | 0.16 | ||
BD, blood donors; CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; MC, mixed cryoglobulinemia; NHL, non-Hodgkin lymphoma; ∗MAF, minor allele frequency, corresponding to deletion (del) in TLR2 and T-allele in IFNL3; OR, odds ratio; 95% CI, 95% confidence interval; †only significant results have been reported.